Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 88 PAGES: 101

More Info
									       Idiopathic Thrombocytopenic Purpura (Immune
   Thrombocytopenic Purpura) – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1920IDB
                                                                                              Publication Date: April 2012




Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) –                       GMDHC1920IDB / Pub April 2012
Pipeline Review, H1 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic
Purpura) – Pipeline Review, H1 2012



Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 6
    List of Figures ................................................................................................................................................................................ 7
Introduction......................................................................................................................................................................................... 8
    Global Markets Direct Report Coverage ........................................................................................................................................ 8
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview.................................................................... 9
Therapeutics Development............................................................................................................................................................... 10
    An Overview of Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura).................. 10
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics under Development by Companies .... 12
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics under Investigation by
Universities/Institutes ....................................................................................................................................................................... 14
Late Stage Products ......................................................................................................................................................................... 16
    Comparative Analysis .................................................................................................................................................................. 16
Mid Clinical Stage Products.............................................................................................................................................................. 17
    Comparative Analysis .................................................................................................................................................................. 17
Pre-Clinical Stage Products.............................................................................................................................................................. 18
    Comparative Analysis .................................................................................................................................................................. 18
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics – Products under Development by
Companies ....................................................................................................................................................................................... 19
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics – Products under Investigation by
Universities/Institutes ....................................................................................................................................................................... 20
Companies Involved in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Development . 21
    Amgen Inc. .................................................................................................................................................................................. 21
    AstraZeneca PLC ........................................................................................................................................................................ 22
    GlaxoSmithKline plc .................................................................................................................................................................... 23
    Cangene Corporation .................................................................................................................................................................. 24
    Symphogen A/S........................................................................................................................................................................... 25
    Eisai Co., Ltd. .............................................................................................................................................................................. 26
    IMMUNOMEDICS, INC ............................................................................................................................................................... 27
    Maywufa Company Limited ......................................................................................................................................................... 28
    Bio Products Laboratory .............................................................................................................................................................. 29
    SuppreMol GmbH ........................................................................................................................................................................ 30
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics Assessment .................................... 31
    Assessment by Monotherapy Products ....................................................................................................................................... 31
    Assessment by Combination Products ........................................................................................................................................ 32
    Assessment by Route of Administration ...................................................................................................................................... 33
    Assessment by Molecule Type .................................................................................................................................................... 35
Drug Profiles..................................................................................................................................................................................... 37
    Veltuzumab - Drug Profile ........................................................................................................................................................... 37
         Product Description................................................................................................................................................................. 37
         Mechanism of Action ............................................................................................................................................................... 37
         R&D Progress ......................................................................................................................................................................... 37
    Nplate - Drug Profile .................................................................................................................................................................... 39

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) –                                                                            GMDHC1920IDB / Pub April 2012
Pipeline Review, H1 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic
Purpura) – Pipeline Review, H1 2012



        Product Description................................................................................................................................................................. 39
        Mechanism of Action ............................................................................................................................................................... 39
        R&D Progress ......................................................................................................................................................................... 39
    E5501 - Drug Profile .................................................................................................................................................................... 41
        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
    Sym001 - Drug Profile ................................................................................................................................................................. 43
        Product Description................................................................................................................................................................. 43
        Mechanism of Action ............................................................................................................................................................... 43
        R&D Progress ......................................................................................................................................................................... 43
    Alemtuzumab + Rituximab - Drug Profile..................................................................................................................................... 45
        Product Description................................................................................................................................................................. 45
        Mechanism of Action ............................................................................................................................................................... 45
        R&D Progress ......................................................................................................................................................................... 45
    PHN011 - Drug Profile ................................................................................................................................................................. 47
        Product Description................................................................................................................................................................. 47
        Mechanism of Action ............................................................................................................................................................... 47
        R&D Progress ......................................................................................................................................................................... 47
    PHN012 - Drug Profile ................................................................................................................................................................. 49
        Product Description................................................................................................................................................................. 49
        Mechanism of Action ............................................................................................................................................................... 49
        R&D Progress ......................................................................................................................................................................... 49
    PHN013 - Drug Profile ................................................................................................................................................................. 51
        Product Description................................................................................................................................................................. 51
        Mechanism of Action ............................................................................................................................................................... 51
        R&D Progress ......................................................................................................................................................................... 51
    Dexamethasone - Drug Profile .................................................................................................................................................... 53
        Product Description................................................................................................................................................................. 53
        Mechanism of Action ............................................................................................................................................................... 53
        R&D Progress ......................................................................................................................................................................... 53
    Prednisolone - Drug Profile ......................................................................................................................................................... 54
        Product Description................................................................................................................................................................. 54
        Mechanism of Action ............................................................................................................................................................... 54
        R&D Progress ......................................................................................................................................................................... 54
    Dexamethasone - Drug Profile .................................................................................................................................................... 55
        Product Description................................................................................................................................................................. 55
        Mechanism of Action ............................................................................................................................................................... 55
        R&D Progress ......................................................................................................................................................................... 55
    Dexamethasone + MabThera - Drug Profile ................................................................................................................................ 56
        Product Description................................................................................................................................................................. 56
        Mechanism of Action ............................................................................................................................................................... 56
        R&D Progress ......................................................................................................................................................................... 57
    Dexamethasone - Drug Profile .................................................................................................................................................... 58

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) –                                                                       GMDHC1920IDB / Pub April 2012
Pipeline Review, H1 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(3)
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic
Purpura) – Pipeline Review, H1 2012



        Product Description................................................................................................................................................................. 58
        Mechanism of Action ............................................................................................................................................................... 58
        R&D Progress ......................................................................................................................................................................... 58
    Rituximab + Dexamethasone - Drug Profile ................................................................................................................................ 60
        Product Description................................................................................................................................................................. 60
        Mechanism of Action ............................................................................................................................................................... 60
        R&D Progress ......................................................................................................................................................................... 60
    Gammaplex - Drug Profile ........................................................................................................................................................... 62
        Product Description................................................................................................................................................................. 62
        Mechanism of Action ............................................................................................................................................................... 62
        R&D Progress ......................................................................................................................................................................... 62
    Prednisone - Drug Profile ............................................................................................................................................................ 63
        Product Description................................................................................................................................................................. 63
        Mechanism of Action ............................................................................................................................................................... 63
        R&D Progress ......................................................................................................................................................................... 63
    GSK2285921 - Drug Profile ......................................................................................................................................................... 65
        Product Description................................................................................................................................................................. 65
        Mechanism of Action ............................................................................................................................................................... 65
        R&D Progress ......................................................................................................................................................................... 65
    R788 - Drug Profile ...................................................................................................................................................................... 66
        Product Description................................................................................................................................................................. 66
        Mechanism of Action ............................................................................................................................................................... 66
        R&D Progress ......................................................................................................................................................................... 66
    Dexamethasone U
								
To top